Galectin-9 Induced by Dietary Prebiotics Regulates Immunomodulation to Reduce Atopic Dermatitis Symptoms in 1-Chloro-2,4-Dinitrobenzene (DNCB)-Treated NC/Nga Miceopen access
- Kim, Jeong A.; Kim, Sung Hak; Kim, In Sung; Yu, Yoon; Kim, Gwang Il; Moon, Yang Soo; Kim, Sung Chan; Lee, Seung Ho; Lee, Sang Suk; Yun, Cheol Heui; Choi, In Soon; Cho, Kwang Keun
- Issue Date
- KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
- Gut microbiota; immunomodulation; prebiotics; Th1 cells; Th2 cells; Treg cells
- JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, v.30, no.9, pp.1343 - 1354
- Journal Title
- JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
- Start Page
- End Page
- Atopic dermatitis (AD) is a skin disorder that causes chronic itch. We investigated the inhibitory effects of a mixture of prebiotic short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS), inulin, or beta-glucan on AD development in 1-chloro-2,4-dinitrobenzene (DNCB)-treated NC/Nga mice. Mice were randomly assigned to six groups: untreated mice, AD control, positive control (DNCB-treated NC/Nga mice fed a dietary supplement of Zyrtec), and DNCB-treated NC/Nga mice fed a dietary supplement of prebiotics such as scGOS/lcFOS (T1), inulin (T2), or beta-glucan (T3). The prebiotic treatment groups (T1, T2, and T3) showed suppression of AD symptoms, Th2 cell differentiation, and AD-like skin lesions induced by DNCB. In addition, prebiotic treatment also reduced the number of microorganisms such as Firmicutes, which is associated with AD symptoms, and increased the levels of Bacteroidetes and Ruminococcaceae, which are associated with alleviation of AD symptoms. Our findings demonstrate the inhibitory effects of prebiotics on AD development by improving the Th1/Th2 cytokine balance and beneficial symbiotic microorganisms in in vitro and in vivo models.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 농업생명과학대학 > 축산과학부 > Journal Articles
- 농업생명과학대학 > 동물생명융합학부 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.